Kath joined Brandon Capital in 2016.
Prior to joining, Kath was based in academia working in the field of experimental stroke. She spent 5 years at Weill Cornell Medicine-New York Presbyterian Hospital as a NHMRC CJ Martin and American Australian Association Sir Keith Murdoch fellow, before returning to the Florey Institute in Melbourne. During her time in academia she secured competitive research funding from both the NHMRC and Brain Foundation of Australia.
Kath is a board observer of Allay Therapeutics.
Kath has a Bachelor of Science (Honours) from The University of Melbourne, a PhD in Pharmacology from the University of Melbourne and an MBA (Deans’ Honours list) from the Melbourne Business School.